ERBB2 and neoplasm: For HER2 status prediction, Wang et al. (2025) [20] proposed a dual-modality framework combining MM and MRI data, combining handcrafted and deep features to differentiate HER2-zero, HER2-low, and HER2-positive tumor, aligning with the growing clinical importance of accurately identifying HER2-low patients for emerging targeted therapies.